Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cidofovir

Next Previous
X
Search
Drug Profile

Cidofovir

Alternative Names: Forvade®; GS 504; HPMPC; Vistide

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague); Pfizer; Rega Institute for Medical Research; University of Texas M. D. Anderson Cancer Center
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cytomegalovirus retinitis
  • No development reported Cystitis
  • Discontinued Cancer; Herpes simplex virus infections; Human papillomavirus infections; Kaposi's sarcoma; Molluscum contagiosum; Polyomavirus infections; Rheumatic disorders; Viral infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cystitis in USA (Intravesicular, Liquid)
  • 01 Dec 2016 Gilead Sciences completes a phase I trial in Cystitis (in patients who have undergone haematopoietic stem cell transplant) in USA (Intravesicular) (NCT01816646)
  • 06 Sep 2013 Phase-I clinical trials in Cystitis (in patients who have undergone haematopoietic stem cell transplant) in USA (Intravesicular) (NCT01816646)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top